NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
PRCT
PROCEPT BioRobotics Corporation
PRCT has the edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PRCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
PRCT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PRCT PE Valuation
PRCT has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PRCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PRCT has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PRCT on earnings quality, reporting a profit while its opponent remains loss making.
PRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.03 | -$0.51 |
| Q2 2026 | -$1.95 | -$0.41 |
| Q1 2026 | -$1.83 | -$0.14 |
| Q4 2025 | -$1.72 | +$0.03 |
| Q3 2025 | -$1.52 | +$0.43 |
| Q2 2025 | -$1.54 | +$0.52 |
| Q1 2025 | -$1.69 | +$0.43 |
| Q4 2024 | -$1.75 | +$0.49 |
PRCT lost $2.03 per share over the past year, a bigger loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PRCT on profitability, with a higher operating margin.
PRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $98.3M | +18% |
| Q2 2026 | $94.5M | +19% |
| Q1 2026 | $83.1M | +20% |
| Q4 2025 | $76.4M | +12% |
| Q3 2025 | $83.3M | +43% |
| Q2 2025 | $79.2M | +48% |
| Q1 2025 | $69.2M | +55% |
| Q4 2024 | $68.2M | +57% |
PRCT has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | 0 points |
| Q2 2026 | -29% | -1 points |
| Q1 2026 | -39% | +0.5 points |
| Q4 2025 | -41% | -12 points |
| Q3 2025 | -28% | +11 points |
| Q2 2025 | -28% | +22 points |
| Q1 2025 | -40% | +22 points |
| Q4 2024 | -29% | +39 points |
PRCT's operating margin was −28% last quarter, about level with the same quarter a year ago, near the top of its range since 2020.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PRCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.7M | -$149K |
| Q2 2026 | -$22.2M | -$4.4M |
| Q1 2026 | -$41M | -$22.2M |
| Q4 2025 | -$12.2M | +$21.4M |
| Q3 2025 | -$9.5M | +$9.5M |
| Q2 2025 | -$17.8M | -$1.1M |
| Q1 2025 | -$18.8M | +$15.4M |
| Q4 2024 | -$33.6M | -$57K |
PRCT has burned cash in almost every quarter: −$85M over the past year, against −$80M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PRCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +259K shares |
| 1 year | +2.9% | +1.6M shares |
| 3 years | +19% | +9M shares |
| 5 years | +39% | +16.1M shares |
PRCT has 57M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PRCT Net Leverage
PRCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.6 | Neutral |
| Stochastic | 60.7 | Neutral |
PRCT's weekly RSI is 55 (neutral) and its Stochastic is 61 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRCT PE vs Healthcare Sector
PRCT has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 22% above |
| 20 week MA | $19.9 | 18% above |
| 50 week MA | $24.5 | 3.8% below |
| 100 week MA | $39.0 | 40% below |
| 200 week MA | $44.3 | 47% below |
PRCT has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over PRCT on returns for 2026, with the stronger performance.
PRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $40.0 | $27.0 | -32% |
| 2022 | $27.0 | $40.9 | +51% |
| 2023 | $40.9 | $41.9 | +2.4% |
| 2024 | $41.9 | $82.0 | +96% |
| 2025 | $82.0 | $32.4 | -60% |
| 2026 YTD | $32.4 | $23.5 | -27% |
PRCT has finished higher in three of the last five years, two of them by more than 50%. It's down 27% so far in 2026.